New Hope for Stargardt Disease as Alkeus Presents Key Data at ARVO

CAMBRIDGE, MA – April 30, 2026 – In a significant development for patients with Stargardt disease, Alkeus Pharmaceuticals announced today that it will present new data from its clinical program for gildeuretinol (ALK-001), an investigational oral therapy. The presentation, set for the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting in Denver, offers a glimpse into the progress of a potential first-ever treatment for the rare genetic condition, which is a leading cause of incurable blindness in children and young adults.

The poster presentation on May 7 will detail the baseline characteristics of patients enrolled in the company’s pivotal TEASE (Tolerability and Effects of ALK-001 on Stargardt Disease) clinical program. While not a release of efficacy results, this type of data is critical for the scientific community to understand the patient population being studied and to contextualize future outcomes for a drug that has already received multiple fast-track designations from regulators.

A Devastating Disease with No Approved Treatment

Stargardt disease is the most common form of inherited macular degeneration, affecting an estimated 37,000 to 87,000 people in the United States alone. The condition is caused by mutations in the ABCA4 gene, which leads to a defective protein responsible for clearing byproducts of the visual cycle. As a result, toxic vitamin A dimers and cellular waste known as lipofuscin accumulate in the retina, progressively destroying the light-sensing photoreceptor cells in the macula—the central part of the retina responsible for sharp, detailed vision.

Symptoms typically emerge in childhood or adolescence, beginning with difficulty seeing in low light and the appearance of central blind spots, or scotomas. As the disease progresses, it robs young individuals of their ability to read, recognize faces, or drive, profoundly impacting their quality of life and independence. Despite its prevalence among inherited retinal diseases, there are currently no FDA-approved treatments to slow, stop, or reverse the vision loss associated with Stargardt disease. Management is limited to supportive care, such as low-vision aids and lifestyle adjustments.

A Novel Oral Drug Shows Promise

Alkeus Pharmaceuticals’ gildeuretinol represents a novel pharmacological approach to tackling the disease at its source. The investigational drug is a chemically modified form of vitamin A, known as a selectively-deuterated molecule. This modification is designed to slow the rate at which vitamin A forms toxic dimers, effectively reducing the accumulation of the harmful byproducts that damage retinal cells. Because it is administered as a daily oral pill, it offers a non-invasive alternative to the complex surgical procedures required for many gene therapies.

The Cambridge-based company's TEASE clinical program has already generated significant optimism. Results from the completed Phase 2 TEASE-1 trial, which enrolled 50 patients, demonstrated that gildeuretinol slowed the growth of atrophic retinal lesions by a statistically significant 21.6% over two years compared to a placebo. Furthermore, promising interim results from the TEASE-3 study, which focuses on presymptomatic adolescents, have shown that early intervention may prevent disease progression and preserve stable vision over several years.

This progress has not gone unnoticed by regulatory bodies. The U.S. Food and Drug Administration (FDA) has granted gildeuretinol a powerful combination of designations for Stargardt disease, including Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease status. These designations are reserved for therapies that address serious conditions with high unmet need and indicate that regulators see substantial potential in the drug, allowing for a more expedited development and review pathway.

The Race for a Cure Heats Up

The push to find a treatment for Stargardt disease has fostered a competitive and rapidly advancing therapeutic landscape. Alkeus is a frontrunner, but several other companies are making significant strides with different approaches. Belite Bio’s oral candidate, tinlarebant, which also aims to reduce vitamin A-based toxins, has shown positive Phase 3 results and is on a similar timeline for a potential New Drug Application (NDA) filing in 2026.

Beyond oral medications, the field is rich with cutting-edge gene and cell-based therapies. Ocugen is advancing OCU410ST, a gene-modifier therapy, into late-stage trials, while Nanoscope Therapeutics is developing an optogenetic therapy, MCO-010, designed to restore light sensitivity in patients with advanced retinal degeneration. Companies like SpliceBio and AAVantgarde Bio are tackling the challenge of delivering a functional copy of the large ABCA4 gene via AAV vectors. This intense competition underscores the urgency of the unmet need and the immense commercial opportunity, with market forecasts projecting the Stargardt treatment market to potentially exceed $2 billion by the early 2030s.

Strategic Steps Toward a Potential New Era

For Alkeus, the upcoming ARVO presentation is a strategic step in its journey toward commercialization. By sharing baseline data, the company engages in transparent scientific discourse and lays the groundwork for the highly anticipated efficacy and safety results from its later-stage trials. The presentation will be delivered by Dr. Ryan Yanagihara of Retina Consultants of Texas, a key investigator in the field.

Behind this scientific progress is a company fortified for success. In June 2023, Alkeus secured a landmark $150 million Series B financing round led by premier investor Bain Capital Life Sciences. This infusion of capital is explicitly aimed at funding the final stages of clinical development, supporting a planned NDA submission, and preparing for a potential commercial launch. The company’s leadership has also been strengthened by the appointment of biotech industry veteran Dr. Joshua Boger, founder of Vertex Pharmaceuticals, as its Executive Chairman, adding deep experience in bringing transformative drugs to market.

With a promising oral drug, strong clinical data, significant regulatory support, and robust financial backing, Alkeus is well-positioned to potentially deliver the first-ever approved therapy for Stargardt disease. The data shared at ARVO will be another important milestone on that path, offering patients and their families a tangible glimmer of hope for a future with preserved sight.